Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
2025-03-27 20:31:03 ET
Clearside Biomedical, Inc. (CLSD)
Q4 2024 Earnings Conference Call
March 27, 2025, 04:30 PM ET
Company Participants
Jenny Kobin - IR
George Lasezkay - CEO
Victor Chong - Chief Medical Officer
Charlie Deignan - CFO
Conference Call Participants
Jon Wolleben - Citizens
Serge Belanger - Needham & Company
Debanjana Chatterjee - JonesTrading
Yi Chen - H.C. Wainwright
Daniil Gataulin - Chardan
Presentation
Operator
Greetings, and welcome to the Clearside Biomedical Fourth Quarter 2024 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode and a question and answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to your host, Jenny Kobin of Investor Relations. Ma'am, the floor is yours.
Jenny Kobin
Good afternoon, everyone, and thank you for joining us on the call today.
Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements, various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of our annual Report on Form 10-K for the year ended December 31, 2024, and our other SEC filings available on our website.
In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change.
On today's call, we have George Lasezkay, our Chief Executive Officer, Dr. Victor Chong, our Chief Medical Officer and Head of Research and Development, and Charlie Deignan, our Chief Financial Officer. We also have accompanying slides that are available on Clearside's website in the Events and Presentations section. After our formal remarks, we will open the call for your questions....
Read the full article on Seeking Alpha
For further details see:
Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call TranscriptNASDAQ: CLSD
CLSD Trading
-90.6% G/L:
$0.41 Last:
1,945,057 Volume:
$0.57 Open:



